Takara Bio Inc (4974) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Takara Bio Inc (4974) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH82157D
  • |
  • Pages: 62
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It offers clinical development of gene therapies for cancer treatment. Takara develops and commercializes medical technologies such as cell and gene therapies for cancer and AIDS. The company also develops original research reagents, scientific instruments, and contracted research services that utilize new genetic and cell engineering technologies. It supports biotechnology research by offering basic research and drug discovery and development services. Takara is headquartered in Kusatsu, Japan.

Takara Bio Inc (4974)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Takara Bio Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Rubicon Genomics Raises USD2 Million in Venture Financing 13

Partnerships 14

Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14

Cellink Enters Research Agreement with Takara Bio Europe 15

Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16

WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17

Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18

WaferGen Bio-systems Enters into Research Agreement with Genentech 19

Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20

Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22

Licensing Agreements 23

Dong-A ST Enters into Licensing Agreement with Takara Bio 23

Takara Bio Enters into Licensing Agreement with Kyushu University 24

Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26

Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27

Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28

Takara Bio Enters into Licensing Agreement with ViaCyte 29

Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30

Takara Bio Expands Licensing Agreement With iPS Academia Japan 31

Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32

WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33

Equity Offering 34

WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34

WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35

WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For USD 15 Million 37

Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38

Acquisition 39

Takara Bio Acquires WaferGen Bio-Systems 39

Takara Bio Acquires Rubicon Genomics for USD75 Million 41

Takara Bio Acquires Cellectis, Biotech Company 42

Takara Bio Inc-Key Competitors 43

Takara Bio Inc-Key Employees 44

Takara Bio Inc-Locations And Subsidiaries 45

Head Office 45

Other Locations & Subsidiaries 45

Joint Venture 46

Recent Developments 47

Strategy And Business Planning 47

Jan 30, 2018: Takara Bio: Regarding the establishment of research and manufacturing facilities for products such as regenerative medicine 47

Jan 30, 2018: Takara Bio to Establish a New Facility for the Research and Manufacturing of Regenerative Medical Products 48

Financial Announcements 49

Nov 28, 2017: Takara Bio: Consolidated Financial Statements for the Second Quarter Ended September 30, 2017 49

Product News 51

May 08, 2018: SMARTer ICELL8 technology aids in single-nuclei sequencing of triple-negative breast cancer to uncover chemoresistance evolution 51

01/17/2018: First Patient Enrolled into Phase I/II Clinical Trial of NY-ESO-1siTCR Gene Therapy Against Synovial Sarcoma in Japan 52

Product Approvals 53

Mar 27, 2018: Announcement on product designation of NY-ESO-1siTCR gene therapy product for synoviral sarcoma under SAKIGAKE Designation System by the Ministry of Health, Labour and Welfare 53

Jan 24, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I/II clinical trial of NY-ESO-1-siTCR gene therapy in Japan 54

Clinical Trials 55

May 31, 2018: Takara Bio presents Final results of HF10 Phase II clinical trial at American Society of Clinical Oncology 55

Sep 27, 2017: First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan 56

Jun 01, 2017: Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan 57

May 29, 2017: First patient enrolled into Oncolytic Virus HF10 phase II clinical trial in Japan 58

May 23, 2017: Takara Bio presents HF10 Phase II clinical trial data at American Society of Clinical Oncology 59

Jan 30, 2017: Takara Bio: Announcement on submission of the Clinical Trial Plan Notification for phase II clinical trial of Oncolytic virus HF10 in Japan 60

Other Significant Developments 61

May 17, 2018: Takara Bio Announces Launch of Beta Cell Differentiation Service 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62

List of Figures

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Takara Bio Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Takara Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Takara Bio Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Takara Bio Inc, Medical Devices Deals, 2012 to YTD 2018 10

Takara Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Rubicon Genomics Raises USD2 Million in Venture Financing 13

Takara Bio Enters into Co-Development Agreement with Otsuka Pharma 14

Cellink Enters Research Agreement with Takara Bio Europe 15

Rubicon Genomics Enters into Distribution Agreement with Beckman Coulter Life Sciences for ThruPLEX Plasma-Seq Kits 16

WaferGen Biosystems Enters into Agreement with Luxembourg Institute of Health 17

Rubicon Genomics Enters into Distribution Agreeement with Eurofins MWG Operon 18

WaferGen Bio-systems Enters into Research Agreement with Genentech 19

Clontech Labs Enters Into Technology Integration Agreement With Rubicon Genomics 20

Rubicon Enters Into Technology Integration Agreement With Diagenode For ChIP Sequencing Technology 21

Takara Bio Enters Into Co-Marketing Agreement With Exiqon For miRCURY LNA Products 22

Dong-A ST Enters into Licensing Agreement with Takara Bio 23

Takara Bio Enters into Licensing Agreement with Kyushu University 24

Otsuka Pharma Enters into Licensing Agreement with Takara Bio 25

AmpliPhi Biosciences Enters into License Agreement with Takara Bio 26

Rubicon Genomics Enters into Licensing Agreement with SomaGenics 27

Cellectis Enters into Licensing Agreement with Takara Bio for RetroNectin 28

Takara Bio Enters into Licensing Agreement with ViaCyte 29

Clontech Lab Enters into Licensing Agreement with Broad Institute for Crispr Gene Editing System 30

Takara Bio Expands Licensing Agreement With iPS Academia Japan 31

Takara Bio Enters Into Licensing Agreement With Cellular Dynamics International For RetroNectin 32

WaferGen Biosystems Enters Into Licensing Agreement With Rutgers University For RNA Quality Control Technology 33

WaferGen Bio-systems Raises USD17.25 Million in Public Offering of Common Stock 34

WaferGen Biosystems Raises USD20 Million in Public Offering of Units 35

WaferGen Biosystems Completes Second Tranche Of Private Placement Of Units For USD 15 Million 37

Takara Bio Raises USD112 Million in Public Offering Of Common Stock 38

Takara Bio Acquires WaferGen Bio-Systems 39

Takara Bio Acquires Rubicon Genomics for USD75 Million 41

Takara Bio Acquires Cellectis, Biotech Company 42

Takara Bio Inc, Key Competitors 43

Takara Bio Inc, Key Employees 44

Takara Bio Inc, Other Locations 45

Takara Bio Inc, Subsidiaries 45

Takara Bio Inc, Joint Venture 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Takara Bio Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17743
Site License
USD 500 INR 35485
Corporate User License
USD 750 INR 53228

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com